drugset / Trial / NCT03542994
A Study of EDP1066 in Healthy Participants and Participants With Mild to Moderate Psoriasis and Atopic Dermatitis
RandomizedSequentialDouble-blindTreatment
Summary
Evelo will investigate the safety and tolerability of EDP1066 and its potential to be a medicinal product in healthy volunteers and individuals with mild to moderate psoriasis and atopic dermatitis.
Timeline
- Start
- 2019-04-24
- Primary completion
- 2020-01-03
- Completion
- 2020-01-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | EDP1066 | Unknown | 66 mg | Oral |
| Subject | EDP1066 | Unknown | 660 mg | Oral |
| Subject | EDP1066 | Unknown | 3.3 g | Oral |